

PRESS RELEASE

STOCKHOLM, 26 JUNE 2026 10:45 CEST

Utilization of authorization to acquire own shares

The Board of RaySearch Laboratories AB (publ) has resolved to utilize the authorization to acquire the company's own shares granted by the 2026 Annual General Meeting, for the purpose of adjusting the company's capital structure and thereby contributing to increased shareholder value.

The Board's resolution concerns acquisitions of own Class B shares for a total amount of up to SEK 158.4 million during the period from and including June 26, 2026 up until the 2027 Annual General Meeting, on one or several occasions. Acquisitions may be made of such number of Class B shares that the company's holding of own shares at any time does not exceed five per cent of the total number of shares in the company.

Acquisitions will be made on Nasdaq Stockholm pursuant to Nasdaq Stockholm's Nordic Main Market Rulebook for Issuers of Shares, and in compliance with the pricing restrictions set out therein.

As of the date of this press release, RaySearch holds 380,000 own Class B shares.

Completed acquisitions will be reported to Nasdaq Stockholm in accordance with applicable rules.

For more information, please contact

Carolina Strömlid, Head of Investor Relations, RaySearch Laboratories AB

Tel: +46 (0) 708 807 173

ir@raysearchlabs.com

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure, and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. RaySearch's software has been sold to over 1,200 clinics in 51 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003 (STO: RAY B). More information is available at raysearchlabs.com.

Learn more about us on:

[LinkedIn](#)

[YouTube](#)

** Subject to regulatory clearance in some markets.*

This information is information that RaySearch Laboratories is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-06-26 10:45 CEST.